This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
- Complications of Radioactive Iodine Treatment of Thyroid Carcinoma
- Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation
- 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
- Reducing the Incidence of 131I-Induced Sialadenitis: The Role of Pilocarpine
- Salivary Gland Injury Resulting From Exposure to Radioactive Iodine: Case Reports
- Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases
- A perspective view of sodium iodide symporter research and its clinical implications.
- Increasing Efficacy and Safety of Treatments of Patients with Well-Differentiated Thyroid Carcinoma by Measuring Body Retentions of 131I
- Dosimetry-Guided Radioactive Iodine Treatment in Patients with Metastatic Differentiated Thyroid Cancer: Largest Safe Dose Using a Risk-Adapted Approach
- Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy
- Thyroid Carcinoma with High Levels of Function: Treatment with 131I